Although the protein expression of SRC-1, a typical type of AR adjuvant, showed no significant difference in the BPH group by western blotting, it showed a reduction by TPS treatment, both in the western blotting and IHC assay (Fig. 3B and C). Here, AR is linked to benign prostatic hyperplasia.